Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 54 citing articles:

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi, et al.
The Lancet (2023) Vol. 401, Iss. 10378, pp. 747-761
Closed Access | Times Cited: 187
Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Ana Belén Azuaga, Julio Ramírez, Juan D. Cañete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4901-4901
Open Access | Times Cited: 69
The role of inflammation in autoimmune disease: a therapeutic target
Yu Xiang, Mingxue Zhang, D.Y. Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 51
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Bruce Strober, Laura C. Coates, Mark Lebwohl, et al.
Drug Safety (2023) Vol. 47, Iss. 1, pp. 39-57
Open Access | Times Cited: 25
Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database
Vishnu Eshwar, Ashwin Kamath
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
IL-17A inhibitors alleviate Psoriasis with concomitant restoration of intestinal/skin microbiota homeostasis and altered microbiota function
Huixia Zhao, Lili Shang, Yuting Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
Vishnu Eshwar, Ashwin Kamath, Rajeshwari Shastry, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1365-1365
Open Access | Times Cited: 29
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure
Mark Lebwohl, Joseph F. Merola, Katelyn Rowland, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 1, pp. 42-52
Open Access | Times Cited: 21
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis
Proton Rahman, Wolf‐­Henning Boehncke, Philip J. Mease, et al.
The Journal of Rheumatology (2023) Vol. 50, Iss. 6, pp. 769-780
Open Access | Times Cited: 13
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials
Atul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
Arthritis Research & Therapy (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 5
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 3, pp. 729-743
Open Access | Times Cited: 5
Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors
Victoria Fang, Radhika Gupta, Robert G. Micheletti
Dermatologic Clinics (2025) Vol. 43, Iss. 2, pp. 231-245
Closed Access
Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea
Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, et al.
Lara D. Veeken (2025)
Closed Access
Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents
Andrea Picchianti Diamanti, Alessandra Aiello, Chiara De Lorenzo, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The preclinical discovery and development of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa
Klaudia Knecht-Gurwin, Łukasz Matusiak, Jacek C. Szepietowski
Expert Opinion on Drug Discovery (2025)
Closed Access
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Peter C. Taylor, Philip J. Mease, Kurt de Vlam, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Lars Erik Kristensen, Bruce Strober, Denis Poddubnyy, et al.
Therapeutic Advances in Musculoskeletal Disease (2023) Vol. 15
Open Access | Times Cited: 12
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy
Stefano Dastoli, Maria Passante, Francesco Loconsole, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 12
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials
Andrew Blauvelt, April W. Armstrong, Joseph F. Merola, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 1, pp. 72-81
Open Access | Times Cited: 4
A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation
Maciej Naumowicz, Stefan Modzelewski, Angelika Macko, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3482-3482
Open Access | Times Cited: 4
Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus
Tiago Torres, Nicolò Costantino Brembilla, Richard Langley, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 4
Therapeutic approaches for SAPHO syndrome from the perspective of pathogenesis: a review of the literature
Yunuo Wang, Mengjiao Gu, Zixiang Zheng, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
Matteo Megna, Cataldo Patruno, Maria Rita Bongiorno, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 5, pp. 2629-2633
Open Access | Times Cited: 17
Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
Joanna Narbutt, Michał Niedźwiedź, Aleksandra Lesiak, et al.
Patient Preference and Adherence (2023) Vol. Volume 17, pp. 421-431
Open Access | Times Cited: 10
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Francesco Molica Colella, Gaetano Zizzo, Vincenzo Parrino, et al.
Advances in Rheumatology (2023) Vol. 63, Iss. 1
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top